What’s New

Latest News

News
Emerging Treatments Expand Atopic Dermatitis Options in the US
03/07/2026
Rebecca Mashaw
The expanding portfolio of atopic dermatitis therapies underscores a pivotal transition from suboptimal traditional treatments toward safer, more individualized care across age groups.
The expanding portfolio of atopic dermatitis therapies underscores a pivotal transition from suboptimal traditional treatments toward safer, more individualized care across age groups.
The expanding portfolio of...
03/07/2026
Allergy & Immunology
Allergy & Immunology
an illustration of a man sitting on the ground holding his head with his profile and brain in the background
News
Indirect Costs Drive $366B Schizophrenia Burden in US
02/27/2026
Brionna Mendoza
A comprehensive economic evaluation reported substantial national and state-level societal costs of schizophrenia in the United States for the 2024 calendar year, estimating a total excess societal cost at $366.8 billion.
A comprehensive economic evaluation reported substantial national and state-level societal costs of schizophrenia in the United States for the 2024 calendar year, estimating a total excess societal cost at $366.8 billion.
A comprehensive economic...
02/27/2026
Psych Congress Network
Psych Congress Network
News
Recall of BioGlo Fluorescein Sodium Strips Cites Manufacturing Compliance Concerns
02/26/2026
Grace Taylor, MS, MA
More than 184 000 containers of BioGlo Fluorescein Sodium Ophthalmic Strips are being recalled nationwide after the US Food and Drug Administration (FDA) cited manufacturing lapses leading to a lack of sterility assurance.
More than 184 000 containers of BioGlo Fluorescein Sodium Ophthalmic Strips are being recalled nationwide after the US Food and Drug Administration (FDA) cited manufacturing lapses leading to a lack of sterility assurance.
More than 184 000 containers of...
02/26/2026
Pharmacy Learning Network
Pharmacy Learning Network
FDA Approval
FDA Approves Zongertinib for HER2-Mutated Metastatic NSCLC
02/26/2026
Emily Estrada
Based on results from the Beamion LUNG-1 trial, the FDA has approved zongertinib for patients with HER2-mutated unresectable or metastatic non-squamous non-small cell lung cancer.
Based on results from the Beamion LUNG-1 trial, the FDA has approved zongertinib for patients with HER2-mutated unresectable or metastatic non-squamous non-small cell lung cancer.
Based on results from the...
02/26/2026
Oncology
Oncology
EMTs assessing a child while a parent watches
News
Results of First Comprehensive Assessment of Pediatric Capabilities of EMS and Fire-Rescue Agencies Published
02/26/2026
New study describes nationwide baseline of prehospital pediatric readiness
New study describes nationwide baseline of prehospital pediatric readiness
New study describes nationwide...
02/26/2026
EMSWorld
EMSWorld
News
FDA Seeks Public Comment on Manufacturing Deviation Reporting for Biologics and HCT/Ps Used in Wound Care
02/25/2026
Jennifer J. Spector, DPM, FACFAS
The FDA has issued a Federal Register notice seeking public comment on the continued approval of reporting requirements for manufacturing deviations involving biologics and human cell and tissue products (HCT/Ps), including many cellular and...
The FDA has issued a Federal Register notice seeking public comment on the continued approval of reporting requirements for manufacturing deviations involving biologics and human cell and tissue products (HCT/Ps), including many cellular and...
The FDA has issued a Federal...
02/25/2026
Wounds
Wounds
News
Epcoritamab Plus Lenalidomide and Rituximab Improves PFS in Relapsed Follicular Lymphoma
02/23/2026
Grace Taylor, MS, MA
In the phase 3 EPCORE FL-1 trial, adding epcoritamab to lenalidomide and rituximab significantly improved response rates and reduced the risk of progression or death by 79% versus R2 alone, positioning the chemotherapy-free triplet as a...
In the phase 3 EPCORE FL-1 trial, adding epcoritamab to lenalidomide and rituximab significantly improved response rates and reduced the risk of progression or death by 79% versus R2 alone, positioning the chemotherapy-free triplet as a...
In the phase 3 EPCORE FL-1...
02/23/2026
First Report Managed Care
First Report Managed Care

Latest Research

Cover Story Jan/Feb
The Dermatologist
Forward Focus: Top Trends in Dermatology for 2026
Vol. 34, Issue 1, Issue February 2026
CLD 2026 Jan Feb cover..png
Cath Lab Digest
Impact of TAVR on Functional vs. Degenerative Mitral Regurgitation
Vol. 34, Issue 1, Issue February 2026

HMP Global Learning Network

Featured Interviews

Gustavo Oderich, MD, Robert Rhee, MD, and Sukgu Han, MD
sponsored video
Gustavo Oderich, MD, Robert Rhee, MD, and Sukgu Han, MD Discuss Evolving Treatment Algorithms in AAA Repair of Short, Angulated Necks
02/27/2026
Gustavo S. Oderich, MD; Robert Rhee, MD; Sukgu Han, MD
Three experts share their perspective on the GORE EXCLUDER Conformable AAA Endoprosthesis.
Three experts share their perspective on the GORE EXCLUDER Conformable AAA Endoprosthesis.
Three experts share their...
02/27/2026
Vascular Disease Management
tourniquet stop the bleed DeBoer
Videos
Pediatric Video Tutorial: Stop the Bleed Part 2—Tourniquet Tips
01/30/2026
Scott DeBoer, RN, MSN, CPEN, CEN, CCRN, CFRN
When it comes to tourniquets, whether for little ones or big people, practice and proper placement can be lifesavers.
When it comes to tourniquets, whether for little ones or big people, practice and proper placement can be lifesavers.
When it comes to tourniquets,...
01/30/2026
EMSWorld
Sri Kota, MSN, BA, APN, AGNP-C, AOCNP
Conference Coverage
Clinical Strategies for the Assessment and Management of Antibody-Drug Conjugate Toxicities
01/30/2026
Sri Kota, MSN, BA, APN, AGNP-C, AOCNP
Sri Kota, MSN, BA, APN, AGNP-C, AOCNP, reviewed the mechanisms, expanding clinical use, and payload-driven toxicities of antibody-drug conjugates, emphasizing practical strategies for toxicity recognition, management, and optimizing patient...
Sri Kota, MSN, BA, APN, AGNP-C, AOCNP, reviewed the mechanisms, expanding clinical use, and payload-driven toxicities of antibody-drug conjugates, emphasizing practical strategies for toxicity recognition, management, and optimizing patient...
Sri Kota, MSN, BA, APN, AGNP-C,...
01/30/2026
Oncology Learning Network APP Institute
CTP News Desk hero image
Viewpoints
Avoiding Audits and Making Sure You Get Paid
01/30/2026
Caroline E. Fife, MD, FAAFP, CWS, FUHM
Noting an increase in audits, Dr. Fife advises clinicians on a prudent product selection process and how to avoid being audited.
Noting an increase in audits, Dr. Fife advises clinicians on a prudent product selection process and how to avoid being audited.
Noting an increase in audits,...
01/30/2026
Wounds
Alison Schram, MD, Memorial Sloan Kettering Cancer Center
Videos
Treating NRG1 Fusion-Positive Non-Small Cell Lung Cancer
01/02/2026
Alison Schram, MD
Alison Schram, MD, discusses the treatment course taken for a case of a patient with non-small cell lung cancer with a CD74-NRG1 gene fusion.
Alison Schram, MD, discusses the treatment course taken for a case of a patient with non-small cell lung cancer with a CD74-NRG1 gene fusion.
Alison Schram, MD, discusses the...
01/02/2026
Oncology
Matthew Regulski, DPM, FFPM, RCPS (Glasgow), DABMSP
Viewpoints
Cutting Costs, Raising Standards: The Case for Evidence-Based CTP Use
12/30/2025
Matthew J. Regulski, DPM, ABMSP, CMET, FAPWH(c)
CMS reimbursement reforms are reshaping the use of skin substitutes in wound care, phasing out high-cost, low-evidence products in favor of therapies backed by rigorous clinical data. New models like WISeR promote prior authorization to...
CMS reimbursement reforms are reshaping the use of skin substitutes in wound care, phasing out high-cost, low-evidence products in favor of therapies backed by rigorous clinical data. New models like WISeR promote prior authorization to...
CMS reimbursement reforms are...
12/30/2025
Wounds
Michael Kappelman
From the AIBD Open Air Studio
The Sherman Prize: Michael Kappelman, MD
12/29/2025
Michael Kappelman, MD
Dr Michael Kappelman, one of the Sherman Prize winners for 2025, speaks from the Open Air Studio at the Advances in IBD meeting about his clinical and research work with pediatric patients with ulcerative colitis or Crohn's disease.
Dr Michael Kappelman, one of the Sherman Prize winners for 2025, speaks from the Open Air Studio at the Advances in IBD meeting about his clinical and research work with pediatric patients with ulcerative colitis or Crohn's disease.
Dr Michael Kappelman, one of the...
12/29/2025
Advances in Inflammatory Bowel Disease Network
CTP News Desk Image
Viewpoints
Observations on Potential Pivots and Continued Change
12/01/2025
Scott Nelson
This speaker expounds on potential trends he sees for CTPs in 2026.
This speaker expounds on potential trends he sees for CTPs in 2026.
This speaker expounds on...
12/01/2025
Wounds
Corey Siegel
Conference Coverage
Corey Siegel, MD, on Improving IBD Care Models
11/28/2025
Corey A. Siegel, MD, MS
In the J Edward Burke Distinguished Lecture at the ACG Scientific Meeting, Dr Corey Siegel outlined 5 problems in advancing the care of patients with inflammatory bowel disease, and discussed how the RADIUS program begun at his institution...
In the J Edward Burke Distinguished Lecture at the ACG Scientific Meeting, Dr Corey Siegel outlined 5 problems in advancing the care of patients with inflammatory bowel disease, and discussed how the RADIUS program begun at his institution...
In the J Edward Burke...
11/28/2025
Advances in Inflammatory Bowel Disease Network
BDHC thumbnail
Videos
Breaking Down Cancer Prevention: What Really Works?
11/26/2025
John Hennessy, MBA; Michael Kolodziej, MD
In this episode of Breaking Down Health Care, John Hennessy and Dr. Michael Kolodziej explore the crucial difference between cancer screening and true cancer prevention, highlighting how lifestyle changes, vaccines, and emerging therapies...
In this episode of Breaking Down Health Care, John Hennessy and Dr. Michael Kolodziej explore the crucial difference between cancer screening and true cancer prevention, highlighting how lifestyle changes, vaccines, and emerging therapies...
In this episode of Breaking Down...
11/26/2025
Cancer Care Business Exchange

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use